Literature DB >> 26412796

Pathophysiology of Osteonecrosis of the Jaws.

Tara Aghaloo1, Renna Hazboun2, Sotirios Tetradis3.   

Abstract

Osteonecrosis of the jaw (ONJ) is a multifactorial disease in patients with primary or metastatic bone malignancy or osteoporosis undergoing systemic antiresorptive therapy, where pathophysiology has not yet been fully determined. The staging of ONJ is based on severity of symptoms and extent of clinical and radiographic findings. Treatment strategies range from conservative local wound care to aggressive resective surgery of all necrotic bone. The first ONJ cases were reported in 2003 and 2004, and although significant progress has been made in our understanding of the disease, much more work needs to be done to completely explain its pathophysiology.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiresorptive; Bisphosphonates; MRONJ; Osteonecrosis of the jaws (ONJ); Pathophysiology

Mesh:

Substances:

Year:  2015        PMID: 26412796      PMCID: PMC4908822          DOI: 10.1016/j.coms.2015.06.001

Source DB:  PubMed          Journal:  Oral Maxillofac Surg Clin North Am        ISSN: 1042-3699            Impact factor:   2.802


  98 in total

1.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

2.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

3.  Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?

Authors:  Hani Mawardi; Nathaniel Treister; Paul Richardson; Kenneth Anderson; Nikhil Munshi; Robert A Faiella; Sook-Bin Woo
Journal:  J Oral Maxillofac Surg       Date:  2009-03       Impact factor: 1.895

4.  Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

Authors:  Estee P Wang; Leonard B Kaban; Gordon J Strewler; Noopur Raje; Maria J Troulis
Journal:  J Oral Maxillofac Surg       Date:  2007-07       Impact factor: 1.895

5.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

Review 6.  Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.

Authors:  D B Kimmel
Journal:  J Dent Res       Date:  2007-11       Impact factor: 6.116

Review 7.  Osteonecrosis of the femoral head: evaluation and treatment.

Authors:  Charalampos G Zalavras; Jay R Lieberman
Journal:  J Am Acad Orthop Surg       Date:  2014-07       Impact factor: 3.020

8.  Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.

Authors:  Drake W Williams; Cindy Lee; Terresa Kim; Hideo Yagita; Hongkun Wu; Sil Park; Paul Yang; Honghu Liu; Songtao Shi; Ki-Hyuk Shin; Mo K Kang; No-Hee Park; Reuben H Kim
Journal:  Am J Pathol       Date:  2014-08-28       Impact factor: 4.307

9.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Authors:  C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

10.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12
View more
  39 in total

1.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

2.  Effects of Bisphosphonate Administration on Cleft Bone Graft in a Rat Model.

Authors:  Nicole Cheng; Juyoung Park; Jeffrey Olson; Taewoo Kwon; Deborah Lee; Rachel Lim; Sandy Ha; Reuben Kim; Xinli Zhang; Kang Ting; Sotirios Tetradis; Christine Hong
Journal:  Cleft Palate Craniofac J       Date:  2017-01-17

3.  CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.

Authors:  Akira Baba; Tazuko K Goto; Hiroya Ojiri; Mutsumi Takagiwa; Chiho Hiraga; Masahiro Okamura; Sho Hasegawa; Yumi Okuyama; Nobuhiro Ogino; Hideomi Yamauchi; Yuko Kobashi; Shinji Yamazoe; Yohei Munetomo; Takuji Mogami; Takeshi Nomura
Journal:  Dentomaxillofac Radiol       Date:  2018-02-13       Impact factor: 2.419

4.  Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease.

Authors:  Akrivoula Soundia; Danny Hadaya; Navid Esfandi; Rafael Scaf de Molon; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Tara Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2016-06-18       Impact factor: 4.398

5.  Indigenous Microbiota Protects against Inflammation-Induced Osteonecrosis.

Authors:  D W Williams; H E Vuong; S Kim; A Lenon; K Ho; E Y Hsiao; E C Sung; R H Kim
Journal:  J Dent Res       Date:  2020-02-28       Impact factor: 6.116

Review 6.  [Progress on medication-related osteonecrosis of the jaw].

Authors:  Qi-Zhang Wang; Ji-Yuan Liu; Jian Pan
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2018-10-01

7.  Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ).

Authors:  Ioannis Gkouveris; Danny Hadaya; Akrivoula Soundia; Olga Bezouglaia; Yee Chau; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2019-04-03       Impact factor: 4.398

8.  Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.

Authors:  Rafael Scaf de Molon; Chingyun Hsu; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Akrivoula Soundia; Fernando Queiroz Cunha; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2016-05-04       Impact factor: 6.741

9.  Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw.

Authors:  Tarek Metwally; Andrea Burke; Jeffrey Y Tsai; Michael T Collins; Alison M Boyce
Journal:  J Oral Maxillofac Surg       Date:  2016-04-07       Impact factor: 1.895

10.  Impact of communication between physicians and dentists on the incidence of jaw osteonecrosis caused by bone anti-resorptives.

Authors:  Sunday O Akintoye; Elliot V Hersh
Journal:  Curr Med Res Opin       Date:  2016-05-18       Impact factor: 2.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.